| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2019 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 20,000 | $19.76 | $395,116.00 | -9.8% | |
| Nov 6, 2019 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 5,000 | $36.98 | $184,900.00 | +6.4% | |
| Nov 6, 2019 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 75,000 | $37.30 | $2,797,560.00 | +2.1% | |
| Nov 6, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Bolles Albert D. | Chief Executive Officer | Buy | 4,650 | $10.73 | $49,895.50 | +9.9% | |
| Nov 5, 2019 | BMY Bristol Myers Squibb Co | Schmukler Louis S | Pres., Global Mfg. &Supply | Sell | 25,000 | $56.56 | $1,414,000.00 | -43.9% | |
| Nov 5, 2019 | AMRN Amarin Corp Plc\uk | Ekman Lars73 | Director | Sell | 6,400 | $18.00 | $115,230.08 | -100% | |
| Nov 5, 2019 | TEVA Teva Pharmaceutical Industries Ltd | McClellan Michael James | EVP, Chief Financial Officer | Sell | 242 | $8.83 | $2,137.85 | -1.5% | |
| Nov 5, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 10,000 | $10.38 | $103,800.00 | +0.3% | |
| Nov 5, 2019 | BMY Bristol Myers Squibb Co | Elicker John E | SVP, Public Affairs &IR | Sell | 15,000 | $56.66 | $849,900.00 | -16.8% | |
| Nov 4, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 7,003 | $114.04 | $798,608.11 | - | |
| Nov 1, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $19.48 | $9,738.00 | -0.7% | |
| Nov 1, 2019 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 10,188 | $100.34 | $1,022,297.54 | -8.6% | |
| Nov 1, 2019 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 5,000 | $100.22 | $501,103.50 | -2.1% | |
| Oct 31, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Burgess Timothy P | Senior VP Of Supply Chain | Buy | 5,100 | $9.74 | $49,674.00 | New | |
| Oct 31, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $114.00 | $21,659,646.35 | - | |
| Oct 31, 2019 | BUDZ Weed, Inc. | Kwestel Elliot | Director Of Weed Israel Ltd. | Sell | 29,050 | $0.43 | $12,459.50 | -4.8% | |
| Oct 25, 2019 | LLY Eli Lilly & Co | Skovronsky Daniel | SVP, CSO, And Pres. Lrl | Buy | 5,000 | $108.61 | $543,050.00 | +7.1% | |
| Oct 25, 2019 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Buy | 72,000 | $2.75 | $198,000.00 | +0.4% | |
| Oct 25, 2019 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Buy | 72,000 | $2.75 | $198,000.00 | +4.9% | |
| Oct 25, 2019 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Buy | 36,000 | $2.75 | $99,000.00 | +58.1% | |
| Oct 25, 2019 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Buy | 72,000 | $2.75 | $198,000.00 | +4.9% | |
| Oct 25, 2019 | LLY Eli Lilly & Co | Ricks David A51 | President &CEO | Buy | 4,615 | $108.38 | $500,173.70 | +3.0% | |
| Oct 25, 2019 | LLY Eli Lilly & Co | White Anne E. | SVP &Pres-lilly Oncology | Buy | 1,000 | $108.84 | $108,840.00 | +4.8% | |
| Oct 25, 2019 | LLY Eli Lilly & Co | Smiley Joshua L58 | SVP And CFO | Buy | 929 | $107.59 | $99,951.11 | +3.0% | |
| Oct 25, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Hudson Executive Capital LP49 | Director | Sell | 16,931 | $63.48 | $1,074,714.80 | -1.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.